Subscribe To
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Ann
Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Data further supports the continued clinical advancement of TIDAL-01, Turnstone’s lead Selected TIL therapy, currently being evaluated in two Phase 1 trials Results also demonstrate the potential for a streamlined and […] The post Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltra...
Read More
Posted: Nov 3 2023, 10:00
Author Name: forextv
Views: 112185